H
Hcs Pharma
Biotech & Life Sciences · Loos, France · Founded 2014
A company specializing in cell imaging MoreLess
HCS Pharma is a French biotechnology company specializing in the development of advanced 3D cellular assays. These assays utilize natural hyaluronic acid-based hydroscaffolds to better mimic tissue microenvironments, providing more predictive tools for drug development. The company primarily serves pharmaceutical and biotech firms looking to enhance their drug discovery processes. Operating in the global biotechnology market, HCS Pharma employs a business model that includes custom assay development and product sales. Revenue is generated through the sale of these specialized assays and related services. Recently, the company has been involved in innovative fundraising efforts, including a EUR 7.3 million raise through a security token offering (STO). This approach highlights their commitment to leveraging cutting-edge financial technologies to support their growth.
Keywords: 3D cellular assays, hydroscaffolds, drug development, biotechnology, pharmaceutical, custom assays, predictive tools, hyaluronic acid, security token offering, cancer research.
Company overview
Hcs Pharma company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2014
- Headquarters
- Loos, France
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 60.2
Valuation & funding
Hcs Pharma funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AEquity / VC | Mar 2022 | $2.2M | $8.8M | Undisclosed | — |
| LATE VC✓Equity / VC | Aug 2021 | $22M | $88M | Global Emerging Markets | ↗ |
| GRANT✓Other financing | Nov 2019 | $0 | — | Undisclosed | — |
| SUPPORT PROGRAMOther financing | Dec 2015 | $0 | — | Eurasanté | ↗ |
| SPINOUT✓Other financing | Jan 2014 | — | — | French National Centre for Scientific Research - CNRS · Ouest Valorisation · CNRS Innovation | — |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $143K | 0% | 2 |
| 2025 | $143K | 0% | 3 |
| 2024 | $143K | 0% | 10 |
| 2023 | $143K | 0% | 20 |
| 2022 | $143K | 0% | 20 |
| 2021 | $143K | -38.1% | — |
| 2020 | $231K | — | — |
Growth signals
Hcs Pharma website traffic
Latest recorded traffic for Hcs Pharma is 4.1K monthly website visits, down 70.7% over the last three months. Hcs Pharma's team grew 0% over the past year.
Comparisons
Hcs Pharma compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Hcs Pharma's talent
Source: Dealroom Talent Intelligence.
Investors
7 investors on Hcs Pharma's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Hcs Pharma has talent and traffic
team presence
In the news
Latest news about Hcs Pharma
Recent press, funding announcements, and product moves mentioning Hcs Pharma — open to read from the original sources.
Market sentiment
What the market is saying about Hcs Pharma
An AI-synthesized read of the highest-engagement posts about Hcs Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hcs Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.